Discover Camcevi. 99th Annual Western Section AUA Meeting, October 1-5, 2023, Lake Tahoe
Discover Camcevi. UroGPO UNIO Member Summit, October 5-7, 2023, Redondo Beach, CA
site-logo
AVAILABLE
TO ORDER
 

This site is intended for use by U.S. residents only.

©2023 CAMCEVI. All rights reserved. WS-CAM-2200004

A CONVENIENT PREFILLED, NO-MIX SYRINGE FOR GnRH AGONIST TREATMENT OF ADVANCED PROSTATE CANCER IN ADULTS

CAMCEVI® is the first sub-Q leuprolide that comes prefilled with no mixing. In an open-label, single-arm study of 137 adults who received 42 mg of CAMCEVI on Day 0 and Week 24, CAMCEVI offered consistent testosterone suppression to castrate levels, after the initial injection, from Week 4 to Week 48.1

See how simple syringe prep can be
PROVEN LEUPROLIDE EFFICACY

PROVEN
LEUPROLIDE EFFICACY

CAMCEVI offers proven leuprolide efficacy in a convenient prefilled,
no-mix syringe.1

See the results
SIMPLIFIED PREPARATION SIMPLIFIED PREPARATION

SIMPLIFIED
PREPARATION

CAMCEVI comes prefilled with no mixing required—simplifying syringe prep for you.1

Learn more about dosing

ADDITIONAL RESOURCES
AND SUPPORT

Access useful resources, information, and more for you and your patients.

See all resources

SIMPLE
ORDERING

Order CAMCEVI through your distribution and GPO partners.

Learn more

HAVE A QUESTION?

Let us simplify it for you.

CONNECT WITH A REPRESENTATIVE

    GET UPDATES

    Stay informed about
    CAMCEVI with regular updates,
    education, and more.

    *Required fields

    IMPORTANT SAFETY INFORMATION

    Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

    CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

    Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

    Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

    Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

    Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

    Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

    Monitor serum levels of testosterone following injection of CAMCEVI.

    Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

    The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

    INDICATION

    CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

    Click here for full Prescribing Information.

    Reference:

    1. CAMCEVI. Prescribing information. Accord BioPharma; May 2021.